21:19 , Nov 10, 2016 |  BC Innovations  |  Translation in Brief

Cutting the cancer fat

Nimbus Therapeutics LLC has shown one of its computationally designed acetyl-Coenzyme A carboxylase (ACC; ACAC) inhibitors, dubbed ND-646 , can block the fatty acid synthesis that fuels growth of lung tumors, and has developed a...
07:00 , Oct 24, 2016 |  BC Week In Review  |  Clinical News

Gilead preclinical data

In a mouse xenograft model of NSCLC, twice-daily 50 and 100 mg/kg oral ND-646 for 6 weeks significantly reduced total lung tumor burden by 80% and 82%, respectively, vs. vehicle-treated controls (p<0.01 for both). Data...
08:00 , Mar 10, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Carnitine palmitoyl transferase 1 (CPT1); CPT2; v-myc myelocytomatosis viral oncogene homolog (MYC; c-Myc)

Cancer INDICATION: Breast cancer Patient sample, mouse and cell studies suggest inhibiting CPT1 or CPT2 could help treat MYC-driven triple-negative breast cancer (TNBC). In TNBC patients, low tumor levels of acetyl-coenzyme A carboxylase β (...
08:00 , Feb 5, 2015 |  BC Innovations  |  Product R&D

Addex's allosterics

Allosteric modulators are slowly filling the clinical pipeline, but finding the right assays to discover and characterize them properly still confounds companies in the space. Addex Therapeutics Ltd. is going back to basics and forging...
07:00 , Jul 22, 2013 |  BC Week In Review  |  Clinical News

Nimbus Discovery preclinical data

In a rat model of diet-induced obesity, once-daily ND-630 reduced weight gain without affecting food intake, improved insulin sensitivity, dose-dependently reduced whole body fat markers, and reduced triglycerides, fatty acids and cholesterol to chow-fed control...
08:00 , Feb 4, 2013 |  BC Week In Review  |  Clinical News

Nimbus Discovery preclinical data

Nimbus said ND-630 inhibited hepatic fatty acid synthesis with an ED50 of 0.14 mg/kg and stimulated whole body fatty acid oxidation at a minimum effective dose of 3 mg/kg in rats. Data were presented at...
07:00 , Mar 15, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes; obesity Acetyl-coenzyme A carboxylase-b (ACACB; ACC2) Mouse studies suggest inhibiting ACC2 could help treat or prevent metabolic diseases. In mice fed a high-fat...
07:00 , May 13, 2010 |  BC Innovations  |  Distillery Techniques

Technology: Assays & screens

Approach Summary Licensing status Publication and contact information Assays & screens Yeast-based screen for the identification of acetyl-coenzyme A carboxylase (ACAC)(ACC) inhibitors A high throughput yeast-based screen could help identify ACAC inhibitors to treat obesity...
08:00 , Mar 11, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Renal disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Renal disease Diabetic nephropathy Acetyl-coenzyme A carboxylase-b (ACACB; ACC2) Genomewide and in vitro studies suggest that a SNP on ACACB could help predict risk for diabetic...
07:00 , Jul 13, 2009 |  BC Week In Review  |  Clinical News

Genomas preclinical data

Genomas Inc. , Hartford, Conn.   Product: SINM PhyzioType System   Indication: Predict risk of statin-induced neuromyopathy   Based on blood samples from 442 subjects on statin treatment, the company characterized 384 SNPs from 222...